Interleukin-6 signaling, soluble glycoprotein 130, and inflammation in heart failure (Q38183314)

30 August 2017

Interleukin-6 signaling, soluble glycoprotein 130, and inflammation in heart failure (English)

1 reference

30 August 2017

0 references

6

Pål Aukrust

0 references

Thor Ueland

series ordinal

5

object named as

Thor Ueland

1 reference

30 August 2017

2

Lars Gullestad

1 reference

30 August 2017

4

Arne Yndestad

1 reference

PubMed ID

24477903

30 August 2017

Erik Tandberg Askevold

series ordinal

1

object named as

Erik Tandberg Askevold

1 reference

30 August 2017

3

Christen P Dahl

1 reference

30 August 2017

1 June 2014

1 reference

Current heart failure reports

30 August 2017

1 reference

30 August 2017

11

1 reference

30 August 2017

2

1 reference

30 August 2017

146-155

1 reference

https://scigraph.springernature.com/pub.10.1007/s11897-014-0185-9

30 August 2017

0 references

cites work

Inflammatory mediators and the failing heart: past, present, and the foreseeable future

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Systemic inflammation in heart failure--the whys and wherefores

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Multimarker approach for the prediction of heart failure incidence in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Multiple biomarkers for risk prediction in chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Inflammatory cytokines in heart failure: mediators and markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

The immune system and cardiac repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Multiple facets of NF-κB in the heart: to be or not to NF-κB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Inflammatory cytokines and postmyocardial infarction remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Post-infarct remodelling: contribution of wound healing and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Regulation of the inflammatory response in cardiac repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

The paradoxical role of inflammation in cardiac repair and regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: results of a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Rosuvastatin in older patients with systolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study].

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

The role of interleukin-6 in the failing heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Neuropoietin, a new IL-6-related cytokine signaling through the ciliary neurotrophic factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Survival pathways in hypertrophy and heart failure: the gp130-STAT axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Interleukin-6 causes myocardial failure and skeletal muscle atrophy in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Leukemia Inhibitory Factor and Interleukin-6 downregulate sarcoplasmic reticulum Ca2+ ATPase (SERCA2) in cardiac myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Relationship between plasma level of cardiotrophin-1 and left ventricular mass index in patients with dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Augmented expression of cardiotrophin-1 in failing human hearts is accompanied by diminished glycoprotein 130 receptor protein abundance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Relationship of interleukin-6 with regional and global left-ventricular function in asymptomatic individuals without clinical cardiovascular disease: insights from the Multi-Ethnic Study of Atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Relationship of CRP, IL-6, and fibrinogen with right ventricular structure and function: the MESA-Right Ventricle Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Activation of signal transducer and activator of transcription 3 protects cardiomyocytes from hypoxia/reoxygenation-induced oxidative stress through the upregulation of manganese superoxide dismutase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Cardiomyocyte-restricted knockout of STAT3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with advanced age

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Cardiotrophin-1: expression in experimental myocardial infarction and potential role in post-MI wound healing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Cardiotrophin-1 stimulation of cardiac fibroblast growth: roles for glycoprotein 130/leukemia inhibitory factor receptor and the endothelin type A receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Leukemia inhibitory factor reduces contractile function and induces alterations in energy metabolism in isolated cardiomyocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

The functional role of the JAK-STAT pathway in post-infarction remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

The pro- and anti-inflammatory properties of the cytokine interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Although IL-6 trans-signaling is sufficient to drive local immune responses, classical IL-6 signaling is obligate for the induction of T cell-mediated autoimmunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Biomarkers of heart failure with normal ejection fraction: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Plasma soluble gp130 levels are increased in older subjects with metabolic syndrome. The role of insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Correlation of soluble gp130 serum concentrations with arterial blood pressure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

The soluble interleukin 6 receptor: mechanisms of production and implications in disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Mechanisms of soluble cytokine receptor generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

The soluble Interleukin 6 receptor: generation and role in inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Serum levels of interleukin-6 and its soluble receptors in patients with hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Soluble glycoprotein 130 predicts fatal outcomes in chronic heart failure: analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Interleukin 6: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Clinical studies in patients with Castleman's disease, Crohn's disease, and rheumatoid arthritis in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Assessing the safety of biologic agents in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Epigallocatechin-3-gallate inhibits IL-6 synthesis and suppresses transsignaling by enhancing soluble gp130 production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Therapeutic blockade of interleukin-6 in chronic inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Continuous Glycoprotein-130–Mediated Signal Transducer and Activator of Transcription-3 Activation Promotes Inflammation, Left Ventricular Rupture, and Adverse Outcome in Subacute Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (SOLVD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0185-9

Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica

21 January 2018

1 reference

12 December 2020

Activation of gp130 transduces hypertrophic signals via STAT3 in cardiac myocytes

1 reference

12 December 2020

Negative inotropic effects of cytokines on the heart mediated by nitric oxide

1 reference

12 December 2020

Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130

1 reference

12 December 2020

Circulating interleukin-6 family cytokines and their receptors in patients with congestive heart failure

1 reference

12 December 2020

Serum levels of soluble interleukin 6 receptor and soluble gp130 are elevated in patients with localized scleroderma

1 reference

12 December 2020

Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study)

1 reference

12 December 2020

Complex of the soluble IL-11 receptor and IL-11 acts as IL-6-type cytokine in hepatic and nonhepatic cells

1 reference

12 December 2020

Elevated circulating levels of tumor necrosis factor in severe chronic heart failure

1 reference

12 December 2020

Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure

1 reference

12 December 2020

The serum levels of soluble intercellular adhesion molecule-1 (sICAM-1) and soluble gp130 (sgp130) in different tumour stages. Correlation between the two parameters in progression of malignancy.

1 reference

12 December 2020

Circulating levels of cytokines and their site of production in patients with mild to severe chronic heart failure

1 reference

12 December 2020

How much is too much? Interleukin-6 and its signalling in atherosclerosis.

1 reference

12 December 2020

Transsignaling of Interleukin-6 Crucially Contributes to Atherosclerosis in Mice

1 reference

12 December 2020

Myocardial gene expression of leukaemia inhibitory factor, interleukin-6 and glycoprotein 130 in end-stage human heart failure

1 reference

12 December 2020

Activation of the cardiac interleukin-6 system in advanced heart failure

1 reference

12 December 2020

Heart failure with preserved ejection fraction

1 reference

12 December 2020

Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy

1 reference

12 December 2020

Novel path to activation of vascular smooth muscle cells: up-regulation of gp130 creates an autocrine activation loop by IL-6 and its soluble receptor

1 reference

12 December 2020

Endotoxin and cytokines alter contractile protein expression in cardiac myocytes in vivo

1 reference

12 December 2020

The nonspecific anti-inflammatory therapy with methotrexate for patients with chronic heart failure

1 reference

12 December 2020

Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)

1 reference

12 December 2020

Soluble IL-6 receptor leads to a paracrine modulation of the IL-6-induced hepatic acute phase response in double transgenic mice.

1 reference

12 December 2020

A form of circulating interleukin-6 receptor component soluble gp130 as a potential interleukin-6 inhibitor in inflammatory bowel disease

1 reference

12 December 2020

Role of gp130-mediated signalling pathways in the heart and its impact on potential therapeutic aspects

1 reference

12 December 2020

Comparison of soluble glycoprotein 130 and cardiac natriuretic peptides as long-term predictors of heart failure progression

1 reference

12 December 2020

Interleukin-6 family of cytokines and gp130

1 reference

12 December 2020

10.1007/S11897-014-0185-9

Identifiers

DOI

1 reference

PubMed ID

24477903

Dimensions Publication ID

30 August 2017

0 references

1 reference

PubMed ID

24477903